Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom
Mark T Gladwin,Robyn J Barst,J Simon R Gibbs,Mariana Hildesheim,Vandana Sachdev,Mehdi Nouraie,Kathryn L Hassell,Jane A Little,Dean E Schraufnagel,Lakshmanan Krishnamurti,Enrico Novelli,Reda E Girgis,Claudia R Morris,Erika Berman Rosenzweig,David B Badesch,Sophie Lanzkron,Oswaldo L Castro,James G Taylor 6th,Jonathan C Goldsmith,Gregory J Kato,Victor R Gordeuk,Roberto F Machado,walk-PHaSST Investigators and Patients
DOI: https://doi.org/10.1371/journal.pone.0099489
IF: 3.7
2014-07-02
PLoS ONE
Abstract:Background: The role of pulmonary hypertension as a cause of mortality in sickle cell disease (SCD) is controversial. Methods and results: We evaluated the relationship between an elevated estimated pulmonary artery systolic pressure and mortality in patients with SCD. We followed patients from the walk-PHaSST screening cohort for a median of 29 months. A tricuspid regurgitation velocity (TRV)≥ 3.0 m/s cuttof, which has a 67-75% positive predictive value for mean pulmonary artery pressure ≥ 25 mm Hg was used. Among 572 subjects, 11.2% had TRV ≥ 3.0 m/sec. Among 582 with a measured NT-proBNP, 24.1% had values ≥ 160 pg/mL. Of 22 deaths during follow-up, 50% had a TRV ≥ 3.0 m/sec. At 24 months the cumulative survival was 83% with TRV ≥ 3.0 m/sec and 98% with TRV < 3.0 m/sec (p < 0.0001). The hazard ratios for death were 11.1 (95% CI 4.1-30.1; p < 0.0001) for TRV ≥ 3.0 m/sec, 4.6 (1.8-11.3; p = 0.001) for NT-proBNP ≥ 160 pg/mL, and 14.9 (5.5-39.9; p < 0.0001) for both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL. Age > 47 years, male gender, chronic transfusions, WHO class III-IV, increased hemolytic markers, ferritin and creatinine were also associated with increased risk of death. Conclusions: A TRV ≥ 3.0 m/sec occurs in approximately 10% of individuals and has the highest risk for death of any measured variable. The study is registered in ClinicalTrials.gov with identifier: NCT00492531.